Get started
Author

Antje Neumann

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
2000 · Elke Jäger, Sacha Gnjatic, et al. · Proceedings of the National Academy of Sciences · 431
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006 · Elke Jäger, Julia Karbach, et al. · Proceedings of the National Academy of Sciences · 217
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
2012 · Kunle Odunsi, Junko Matsuzaki, et al. · Proceedings of the National Academy of Sciences · 202
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
2007 · A Atmaca, S-E Al-Batran, et al. · British Journal of Cancer · 184
PDF
Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival
2009 · Julia Karbach, Sacha Gnjatic, et al. · International Journal of Cancer · 114
Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
2012 · Julia Karbach, Antje Neumann, et al. · Clinical Cancer Research · 99
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
2011 · E. Weidmann, A. Neumann, et al. · Annals of Oncology · 92
PDF
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
2010 · Julia Karbach, Antje Neumann, et al. · Clinical Cancer Research · 80
PDF
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
2003 · Jonathan Cebon, Elke Jäger, et al. · PubMed · 77
Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma
2005 · Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, et al. · Cancer Research · 70
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
2007 · Armin Bender, Julia Karbach, et al. · PubMed · 52
A Systemic Hyperthermia Oncologic Working Group Trial
2003 · A.M. Westermann, G.J. Wiedemann, et al. · Oncology · 30
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer — A phase II study
2008 · Akin Atmaca, Salah-Eddin Al-Batran, et al. · Gynecologic Oncology · 28
Therapeutic Administration of a Synthetic CpG Oligodeoxynucleotide Triggers Formation of Anti-CpG Antibodies
2012 · Julia Karbach, Antje Neumann, et al. · Cancer Research · 24
A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer
2004 · A. Atmaca, A. Maurer, et al. · Journal of Clinical Oncology · 11
Mitomycin C, 5-Fluorouracil, Leucovorin, and Oxaliplatin as a Salvage Therapy for Patients with Cisplatin-Resistant Advanced Gastric Cancer: A Phase I Dose Escalation Trial
2007 · Salah-Eddin Al-Batran, Anne Kerber, et al. · Oncology Research and Treatment · 10
Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer
2004 · S.-E. Al-Batran, A. Atmaca, et al. · Oncology Research and Treatment · 5
Klinische Studien und Nachwuchswissenschaftler in der Onkologie
2013 · Elke Jäger, Antje Neumann · Springer eBooks · 3
Langzeitremission bei malignem Melanom Stadium IV nach antigenspezifischer Immuntherapie
2010 · Antje Neumann, Julia Karbach, et al. · Medizinische Klinik - Intensivmedizin und Notfallmedizin · 2
LUD01–014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC)
2004 · S.-E. Al-Batran, A. Neumann, et al. · Journal of Clinical Oncology · 2
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
2004 · A Bender, J Karbach, et al. · Cancer Cell International · 2
PDF
Data from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
2023 · Julia Karbach, Antje Neumann, et al. · 1
Supplementary Data from Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
2023 · Julia Karbach, Antje Neumann, et al.
PDF
Supplementary Methods and Figure Legend from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
2023 · Julia Karbach, Antje Neumann, et al.
PDF
Supplementary Figure 3 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
2023 · Julia Karbach, Antje Neumann, et al.
PDF
Works count: 36
Citation count: 1,736
H-index: 14
I10-index: 16
Year
Topic
Type